-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As a new type of precision targeted therapy, chimeric antigen receptor T cell (CAR-T) therapy has received a lot of attention in the field of hematological tumors.
[Hematology Department of Yimaitong] organized an inventory and took you to review the recent progress of CAR-T therapy related research and the approval of new drugs.
Click "Related Article Title" to read the relevant original text.
01 Research progress Phase I research shows that the CAR-T drug idecabtagene vicleucel (ide-cel, bb2121) that targets B cell maturation antigen (BCMA) performs better in patients with relapsed and refractory multiple myeloma (MM) Efficacy.
On the basis of this study, a key study (KarMMa study) explored the efficacy and safety of ide-cel in patients with relapsed and refractory MM.
For details, please click: CAR-T cell therapy Idecabtagene Vicleucel in the treatment of relapsed and refractory multiple myeloma: Results of the Phase II KarMMa study, Professor Ghulam Rehman Mohyuddin and others searched from January 1, 2013 to November 15, 2020 in manuscript or abstract All prospective trials involving ≥2 patients with MM have been published in the form to evaluate the efficacy and safety of CAR-T in the treatment of MM.
For details, please click: CAR-T cell treatment of multiple myeloma: a systematic review and meta-analysis of 950 patients.
At present, the risk factors related to disease progression after CAR-T treatment are still unclear.
Professor Laetitia Vercellino and others have explored the possibility of predicting recurrence Treatment of diffuse large B-cell lymphoma (DLBCL) patients with CAR-T cell therapy within one month of progression/recurrence (especially early progression [EP]) factors, the results of the study were recently published on Blood.For details, please click: CAR-T cell therapy to explore risk factors for early progression of R/R DLBCL patients.
In recent years, CD19-targeted CAR-T therapy has challenged allogeneic hematopoietic stem cell transplantation (alloHCT) in relapsed and refractory large B-cell lymphoma (LCBL) Status in treatment.
A study from the University of Heidelberg in Germany compared the efficacy of CAR-T therapy and alloHCT in relapsed and refractory LBCL.
For details, please click: Which cellular immunotherapy is better for relapsed and refractory large B-cell lymphoma? CAR-T therapy VS allogeneic hematopoietic stem cell transplantation J Clin Oncol recently published an online phase I/II clinical study of anti-CD30 CAR-T cells for the treatment of relapsed and refractory Hodgkin’s lymphoma (HL) (NCT02690545 and NCT02917083) result.
For details, please click: Anti-CD30 CAR-T cell therapy for relapsed and refractory HL patients Phase I/II clinical study results announced A multi-center clinical study led by the National Center explored CD19-targeted CAR-T cell therapy after alloHCT Long-term efficacy of relapsed/refractory acute B-lymphocytic leukemia (B-ALL).
For details, please poke: CD19-CART cell therapy for R/R ALL after allogeneic hematopoietic stem cell transplantation 02 New drug approved February 5, 2021, the U.
S.
Food and Drug Administration (FDA) approved lisocabtagene maraleucel for ≥ Adult patients with relapsed and refractory LBCL lymphoma treated with 2 line systemic therapy, including DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma.
For details, please click: FDA Update | Approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma March 5, 2021, FDA accelerated approval of axicabtagene ciloleucel for relapsed and refractory adults who have previously received ≥2 lines of systemic treatment Patients with follicular lymphoma (FL).
For details, please poke: FDA update | Accelerated approval of axicabtagene ciloleucel for the treatment of patients with relapsed and refractory follicular lymphoma.
Poke "Read the original text" and we will make progress together
[Hematology Department of Yimaitong] organized an inventory and took you to review the recent progress of CAR-T therapy related research and the approval of new drugs.
Click "Related Article Title" to read the relevant original text.
01 Research progress Phase I research shows that the CAR-T drug idecabtagene vicleucel (ide-cel, bb2121) that targets B cell maturation antigen (BCMA) performs better in patients with relapsed and refractory multiple myeloma (MM) Efficacy.
On the basis of this study, a key study (KarMMa study) explored the efficacy and safety of ide-cel in patients with relapsed and refractory MM.
For details, please click: CAR-T cell therapy Idecabtagene Vicleucel in the treatment of relapsed and refractory multiple myeloma: Results of the Phase II KarMMa study, Professor Ghulam Rehman Mohyuddin and others searched from January 1, 2013 to November 15, 2020 in manuscript or abstract All prospective trials involving ≥2 patients with MM have been published in the form to evaluate the efficacy and safety of CAR-T in the treatment of MM.
For details, please click: CAR-T cell treatment of multiple myeloma: a systematic review and meta-analysis of 950 patients.
At present, the risk factors related to disease progression after CAR-T treatment are still unclear.
Professor Laetitia Vercellino and others have explored the possibility of predicting recurrence Treatment of diffuse large B-cell lymphoma (DLBCL) patients with CAR-T cell therapy within one month of progression/recurrence (especially early progression [EP]) factors, the results of the study were recently published on Blood.For details, please click: CAR-T cell therapy to explore risk factors for early progression of R/R DLBCL patients.
In recent years, CD19-targeted CAR-T therapy has challenged allogeneic hematopoietic stem cell transplantation (alloHCT) in relapsed and refractory large B-cell lymphoma (LCBL) Status in treatment.
A study from the University of Heidelberg in Germany compared the efficacy of CAR-T therapy and alloHCT in relapsed and refractory LBCL.
For details, please click: Which cellular immunotherapy is better for relapsed and refractory large B-cell lymphoma? CAR-T therapy VS allogeneic hematopoietic stem cell transplantation J Clin Oncol recently published an online phase I/II clinical study of anti-CD30 CAR-T cells for the treatment of relapsed and refractory Hodgkin’s lymphoma (HL) (NCT02690545 and NCT02917083) result.
For details, please click: Anti-CD30 CAR-T cell therapy for relapsed and refractory HL patients Phase I/II clinical study results announced A multi-center clinical study led by the National Center explored CD19-targeted CAR-T cell therapy after alloHCT Long-term efficacy of relapsed/refractory acute B-lymphocytic leukemia (B-ALL).
For details, please poke: CD19-CART cell therapy for R/R ALL after allogeneic hematopoietic stem cell transplantation 02 New drug approved February 5, 2021, the U.
S.
Food and Drug Administration (FDA) approved lisocabtagene maraleucel for ≥ Adult patients with relapsed and refractory LBCL lymphoma treated with 2 line systemic therapy, including DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma.
For details, please click: FDA Update | Approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma March 5, 2021, FDA accelerated approval of axicabtagene ciloleucel for relapsed and refractory adults who have previously received ≥2 lines of systemic treatment Patients with follicular lymphoma (FL).
For details, please poke: FDA update | Accelerated approval of axicabtagene ciloleucel for the treatment of patients with relapsed and refractory follicular lymphoma.
Poke "Read the original text" and we will make progress together
